Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus' Qnexa Gets "Complete Response" Letter From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.

You may also be interested in...



FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies

What Belviq Labeling Means For Other Obesity Drug Sponsors

Arena’s Belviq is the first obesity drug approval in over a decade, but it won’t be the only one for long. A look at the FDA-approved labeling for lorcaserin offers a preview of how the agency could handle similar issues for Qnexa and, further down the line, Contrave.  

Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape

New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.

Related Content

Topics

UsernamePublicRestriction

Register

PS071374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel